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Biomimetic proteoglycan nanoparticles for growth
factor immobilization and delivery†
Nooshin Zandi,a,b Ebrahim Mostafavi, b Mohammad Ali Shokrgozar,c
Elnaz Tamjid,d Thomas J. Webster, b Nasim Annabi *e,f,g and
Abdolreza Simchi*a,h
The delivery of growth factors is often challenging due to their short half-life, low stability, and rapid de-
activation. In native tissues, the sulfated residual of glycosaminoglycan (GAG) polymer chains of proteo-
glycans immobilizes growth factors through the proteoglycans’/proteins’ complexation with nanoscale
organization. These biological assemblies can influence growth factor–cell surface receptor interactions,
cell differentiation, cell–cell signaling, and mechanical properties of the tissues. Here, we introduce a
facile procedure to prepare novel biomimetic proteoglycan nanocarriers, based on naturally derived poly-
mers, for the immobilization and controlled release of growth factors. We developed polyelectrolyte
complex nanoparticles (PCNs) as growth factor nanocarriers, which mimic the dimensions, chemical
composition, and growth factor immobilization of proteoglycans in native tissues. PCNs were prepared by
a polymer–polymer pair reaction method and characterized for physicochemical properties. Fourier
transform infrared spectroscopy (FTIR) analysis indicated that complexation occurred through electro-
static interactions. Transmission electron microscopy (TEM) results showed that the nanocarriers had a
diameter of 60 ± 11 nm and 91 ± 33 nm for dermatan sulfate sodium salt–poly-L-lysine (DS-PLL) and
gum tragacanth–poly-L-lysine (GT-PLL) complexes, respectively. The colloidal nanoparticles were stable
due to their negative zeta potential, i.e. −25 ± 4 mV for DS-PLL and −18 ± 3.5 mV for GT-PLL.
Cytocompatibility of PCNs in contact with human bone marrow stromal cells (HS-5) was confirmed
through a live/dead assay and metabolic activity measurement. In addition, vascular endothelial growth
factor (VEGF) was used to evaluate the ability of PCNs to stabilize growth factors. The capability of PCNs
to preserve VEGF activity for up to 21 days was confirmed by analyzing the metabolic and mitogenic
characteristics of human umbilical vein endothelial cells (HUVECs). Our results demonstrated the potential
applications of these nanoparticles in therapeutic delivery for tissue regeneration applications.
Introduction
During the past decade, considerable efforts have been made
to enhance the bioavailability and biocompatibility of thera-
peutic agents.1 Among the different delivery carriers, polyelec-
trolyte complexes have attracted great attention due to their
well-tolerated properties and potential as delivery vehicles for
drugs, enzymes and proteins, and DNA encapsulation.2
Polyelectrolyte complexes are appropriate for loading charged
drug molecules due to the simple fabrication process, high
drug loading efficiency and efficacy, acceptable structural
stability, and extended circulation in the blood.3
Polyelectrolyte complex structures are made by complexa-
tion of oppositely charged biopolymers in solution at the
molecular level, generally via formation of hydrogen bonds,
and electrostatic and hydrophobic interactions.4–7 Electrostatic
interactions are important intermolecular forces for complex
oppositely charged polymers, which are derived by entropic
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changes through the release of bound counterions.8 Under
non-stoichiometric compositions, nanoparticles (NPs) with
a net charge of the excess component, are formed.9
Polyelectrolyte complex nanoparticles (PCNs) derived from
naturally derived polymers are promising vehicles for active
targeting delivery because natural polymers intrinsically have
cell binding sites and exhibit high biocompatibility.10,11 For
example, negatively charged polysaccharides, such as carboxy-
methyl cellulose,12 dextran sulfate,13 alginate,3 and chondroi-
tin sulfate,14 have been complexed with positively charged
polymers to generate PCNs for drug delivery.15
Glycosaminoglycans (GAG) include different types of long
linear polysaccharide chains containing chondroitin sulfate
(CS), keratan sulfate (KS), dermatan sulfate (DS), heparin (HP),
hyaluronic acid (HA), and heparin sulfate (HS).16 In addition,
GAGs have various negatively charged carboxyl and sulfate
groups that can maintain water in tissues and can be used as
therapeutic agents for the treatment of osteoarthritis, cancer,
bacterial and viral infections, and blood clotting. These biopo-
lymers can regulate cell signalling, migration, and differen-
tiation through specific interactions with various ligands.
Sulfated GAG is often covalently bound to a protein to form
proteoglycans (PG), which derives its function from the GAG
side chain.17
In native tissues, growth factor stabilization and delivery to
cells are driven by various stimuli through complex microen-
vironments. Therefore, the biomimetic milieu enables growth
factor stabilization and delivery, simultaneously. The GAG side
chains of different proteoglycans are responsible for growth
factor stabilization and protection, and signal regulation
through linkage with cell surface receptors.18–20 This motivates
the usage of GAG as a carrier for growth factors. Proteoglycans
have a wide range of sizes, with a core protein ranging from 20
to 400 kDa, and GAG side chains from one or two side chains
such as decorin and biglycan to over 100 side chains like
aggrecan. These structures display nanoscale organizations.21
Therefore, in addition to the chemical functions of proteogly-
cans, their nanoscale structures play a crucial role in their bio-
physical function.21–24
Gum tragacanth (GT) is another biocompatible and bio-
degradable polysaccharide which has been used for the prepa-
ration of delivery vehicles.25 At the near neutral pH, carboxyl
groups of GT are dissociated, forming negative charges to inter-
act with positively charged polymers such as poly-L-lysine (PLL).26
PLL and its derivatives, such as homo-poly-amino acid, are an
important class of biodegradable cationic polymers for bio-
medical and pharmaceutical applications. They have extensively
been studied and utilized as auxiliary agents in drug delivery
systems.27
Different PCNs have been formed by complexing biopoly-
mers, including combinations of chitosan with different nega-
tively charged polymers such as dextran sulfate,28 hyaluronic,29
alginate30 or heparin.31 PCNs could be used to preserve growth
factors from degradation by enzymes along with the desired
release profile. In addition, their nanoscale size allows cross-
ing of the epithelium.32 Huang et al. investigated the mito-
genic properties of vascular endothelial growth factor (VEGF)
using VEGF–PCN complexation up to five days. They used
dextran sulfate as the anionic polymer with different polyca-
tions, including PLL, chitosan, and poly-(ethyleneimine), to
prepare the PCNs.33 Incorporation of chitosan–heparin NPs
with a decellularized vein scaffold was reported in order to
promote vascularization in the scaffold through localizing
VEGF. Results revealed that controlled release of VEGF over 30
days could increase cellular proliferation and infiltration,
extracellular matrix (ECM) generation, and vascularization.31
In addition to the excess attention to other polysaccharides
such as heparin,34 dermatan sulfate (DS) functions as a cofac-
tor in a variety of therapeutics, especially in cell-mediated
tissue regeneration. This biopolymer plays an important role
in binding to and activating extracellular molecules and
growth factors for numerous essential biological processes,
including cell adhesion, migration, proliferation and differen-
tiation.30 However, so far, the use of DS in clinical trials as a
drug delivery platform for promoting therapeutic functions is
limited. Herein, we use VEGF as a model growth factor due to
its short circulation half-life. Also, binding to PCNs could
influence its stability and presentation to growth factor
receptors.33,35 In addition, it has been reported that modified
VEGF with these ECM-binding motifs improved healing in
chronic diabetic wounds and bone defects.36
In the current study, we developed polyelectrolyte NPs that
mimic the size and biochemical function and chemistry of pro-
teoglycans for VEGF protection and immobilization. Biomimetic
proteoglycan NPs were prepared through a combination of PLL
as the polycationic element and two anionic polysaccharides of
GT and dermatan sulfate sodium salt (DS). The engineered NPs
were characterized by size distribution, zeta potential, surface
functional groups, and cytocompatibility against human bone
marrow stromal cells (HS-5). The ability of the PCNs to preserve
VEGF activity was investigated by measuring the metabolic and
mitogenic characteristics of human umbilical vein endothelial
cells (HUVECs) in the presence of PCNs.
Results and discussion
The nanocarrier was formed by the interaction between the
dissociated functional groups: an anionic sulfonate group
(–OSO−3 in the dermatan sulfate polymer) and carboxyl group
(–COO− in GT) with a cationic amino group (–NH3
+) from PLL
without cross-linking, or the use of a surfactant organic
solvent. The physical characteristics (hydrodynamic particle
size, zeta potential, and polydispersity index (PDI)) of PCNs
with different polycation : polyanion mixing ratios in DI water
are shown in Table 1. Fig. 1 demonstrates the schematic for
the chemical building units of the polymers and their inter-
actions to form complex NPs. The process yield was 41 ± 6%
for DS-PLL and 30 ± 5% for GT-PLL. Zeta potential indicated
the negatively charged PCNs (Table 1). The colloidal NPs in DI
water were deemed stable due to their negative zeta potential,
i.e. of −25 ± 4 mV (DS-PLL) and −18 ± 3.5 mV (GT-PLL). These
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structures might form a core/shell configuration, where the
excess polymer in the polyelectrolyte component is located in
the shell, giving the particle the defined charge sign and
colloid stability. The negatively charged PCNs could easily
bind to the positively charged drug and growth factors, which
makes them suitable candidates for delivery of therapeutics.
This method is suitable for encapsulating materials sensitive
to different stress factors such as proteins. The characteristics
of the prepared nanocarriers and their potential to immobilize
VEGF and preserve the growth factor activity were then
studied.
The size and morphology of the PCNs
Representative scanning electron microscopy (SEM) and trans-
mission electron microscopy (TEM) images of PCNs and their
size distribution histogram are shown in Fig. 2a–f. These ana-
lyses indicated individual spherical particles with an average
diameter of 60 ± 11 nm and 91 ± 33 nm for DS-PLL and
GT-PLL NPs, respectively. Also, SEM and TEM images of VEGF-
loaded PCNs are shown in Fig. 1Sa–d.† These analyses indi-
cated individual spherical particles with an average diameter
of 55 ± 8 nm and 103 ± 29 nm for DS-PLL-VEGF and
GT-PLL-VEGF NPs, respectively.
Based on the DLS data reported in Table 1, we selected 1 : 6
and 1 : 10 as the optimum polycation : polyanion mixing ratios
for DS-PLL and GT-PLL, respectively, due to the optimum
values for PDI, hydrodynamic size and zeta potential of NPs.
The result showed a hydrodynamic size of 105 ± 0.5 nm for
DS-PLL and 220 ± 2 nm for GT-PLL with monomodal size dis-
tribution. The larger size of the GT-PLL NPs can be attributed
to the higher molecular weight of GT (180 kDa) as compared
to DS (84 kDa). It is important to mention that the complex
NPs in the solution do not behave like hard spheres, but
rather they are gel-like or have a solid core surrounded by a
charged corona.37 TEM can be used to observe the NPs in the
dry state; however, dynamic light scattering (DLS) enables to
detect the NPs in a solvent. Therefore, the DLS method indi-
cates the hydrodynamic diameter of particles, including the
core with any molecules attached to or adsorbed on the
surface. Solvent molecules bind to the particles through
different non-covalent interactions such as van der Waals
interactions, hydrogen bonding or π–π stacking. The size of
the particles measured by DLS depends on the type of the
Table 1 Hydrodynamic diameter (Dh, nm), polydispersity index (PDI),
and zeta potential (ζ, mV) for DS-PLL and GT-PLL PCNs prepared at
different charge mixing ratios
VPA : VPC Property DS-PLL GT-PLL
1 : 5 Dh 222 ± 8 402 ± 4
PDI 0.11 ± 0.02 0.13 ± 0.05
ζ −27 ± 4 −20 ± 3
1 : 6 Dh 105 ± 0.5 376 ± 3
PDI 0.12 ± 0.05 0.13 ± 0.02
ζ −25 ± 4 −19 ± 2.5
1 : 7 Dh 107 ± 3.5 304 ± 6
PDI 0.2 ± 0.08 0.32 ± 0.07
ζ −21 ± 3 −18.5 ± 3
1 : 10 Dh 102 ± 9 220 ± 2
PDI 0.338 ± 0.3 0.22 ± 0.08
ζ −19 ± 2 −18 ± 3.5
Fig. 1 Schematic representation of nanoparticle formation and their
interaction with the cells. Polyelectrolyte nanoparticles were formed by
the complexation of polycationic PLL (blue) with the polyanionic DS or
GT (red) in excess. These NPs have similar size and composition of the
proteoglycans in the body. PCNs were exposed to hBMSCs to evaluate
their cytocompatibility. The mitogenic and metabolic activity of immobi-
lized VEGF on the PCNs was also evaluated by using HUVECs.
Fig. 2 Characterization of PCNs. Representative scanning electron
microscopy (SEM) images of negatively charged (a) DS-PLL and (b)
GT-PLL NPs. Size histograms for (c) DS-PLL and (d) GT-PLL by measur-
ing the mean diameters of the NPs using ImageJ software (National
Institute of Health, Bethesda, MD). Representative transmission electron
microscopy (TEM) images of (e) DS-PLL and (f ) GT-PLL NPs. FTIR
spectra of (g) raw materials (DS, PLL, and GT) and (h) the synthesized
NPs.
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solvent. Different solvents ensure different solvation character-
istics. Water, which is the PCNs’ media, acts as both a hydro-
gen bond donor and acceptor. The hydrogen bond is a specific
type of strong non-covalent interaction that includes dipole–
dipole attraction between a partially positive hydrogen atom
and a partially negative oxygen, nitrogen, sulfur, or fluorine
atom. Therefore, as expected, the particle sizes measured by
the DLS method were slightly bigger than those measured via
TEM and SEM images.
On the other hand, the zeta potential of DS-PLL was slightly
lower (−25 ± 4 mV) than that of GT-PLL (−18 ± 3.5 mV). This
observation indicates that anionic PCNs were formed.
Nevertheless, DS has strong anionic sulfate groups, while GT is
a mild anionic polysaccharide. Therefore, DS-PLL NPs showed
a lower zeta potential. The size, PDI, and zeta potential of
PCNs after growth factor loading are reported in Table 2. The
magnitude of the zeta potential substantially dropped after
incorporation of VEGF in the PCNs for both types of the PCNs,
whereas the hydrodynamic size of the PCNs did not show sig-
nificant changes after loading of VEGF.
In addition, DLS analysis of DS-PLL and GT-PLL with 1 : 6
and 1 : 10 mixing ratios of polycation : polyanion in cell culture
media is reported in Table 2. The average size distribution of
the particles suspended in the cell culture media was greater
than that in DI water. This indicates that PCNs formed larger
complexes in the media. To that end, the PDI of the particles
suspended in the media were higher than that of those sus-
pended in DI water, implying that the PCNs in the culture
media had broader size distributions. Suspension of the PCNs
in the culture media yielded a lower surface charge density.
The electrostatic binding can explain the interaction between
the proteins in the culture media and negatively charged
PCNs. On the other hand, the lower surface charge density of
the PCNs in the culture media might be derived from adsorp-
tion of uncharged or positively charged amino acids (e.g.
L-glutamine in blood serum).
Furthermore, to evaluate the stability of PCNs under opti-
mized conditions (a concentration of 1 mg ml−1 in acetate
buffer with 0.1 M and pH = 5.5), the hydrodynamic diameter
and zeta potential of NPs were measured 1, 3 and 14 days after
incubation at room temperature. As shown in Fig. 3, no signifi-
cant changes in the hydrodynamic size of the PCNs were
observed. In addition, the zeta potential value remained the
same after 14 days.
Fourier transform infrared spectroscopy
FTIR spectra of pristine GT, PLL, and DS polymers and the
NPs (GT-PLL and DS-PLL) are shown in Fig. 2g and h. Two
features were prominent in the spectrum of PLL, absorbance
in the range 3300 cm−1 and the bands near 1500–1600 cm−1.
The band at 1620–1700 cm−1 was attributed to amide I (mainly
the CO stretching mode) and the band at 1540 cm−1 (amide II)
was related to the in-plane deformational mode of the NH
group.38 Both bands were related to the vibrational modes of
the peptide group. Bands at 1650 and 1429 cm−1 in the FTIR
spectrum of DS were related to axial symmetrical and asymme-
trical deformations of carboxylate anions, respectively.39 The
bands at 1250 and 850 cm−1 were attributed to the axial asym-
metry of SvO groups and the axial deformation of C–O–S.40
Major absorbance bands in GT appeared at 3415 cm−1 (stretch-
ing vibrations of O–H groups), 2945 cm−1 (stretching
vibrations of methylene groups), 1750 cm−1 (various carbonyl
species), 1620 cm−1 (carbonyl stretching vibrations in car-
boxylic acids), 1417 cm−1 (symmetrical stretch of carboxylate
group), 1244 and 115 cm−1 (C–O stretching vibrations of
polyols), and 1080 and 1024 cm−1 (C–O stretching vibrations of
ether and alcohol groups).37 After complexation, peak shifts,
the appearance of new peaks and/or disappearance of some
characteristic peaks, were observed.
In DS-PLL, shifting of the band at 1660 cm−1 to 1560 cm−1
was observed due to vibrations of the residual N–H+ bonds in
PLL. Based on a previous study,41 electrostatic interactions
between PLL and DS can be verified over spectra analysis at
1520 to 1560 cm−1. These bands in the FTIR spectra of the
PCNs showed reduced intensity. The complexation of COO− in
the DS chains with cationic moieties in the PLL polymer
chains can be an explanation of this effect. Electrostatic inter-
actions between NH3
+ of PLL with –OSO3
− groups of DS con-
tributed to the formation of an anionic–cationic polymer
complex. Additional evidence could be the disappearance of
the band at 850 cm−1 for DS after complexation. Instead, the
intensity of a 1250 cm−1 band was enhanced as compared to
DS. Similar changes were noticed in the FTIR spectrum of
GT-PLL. The complexed material showed a narrower band
around 3300 cm−1, due to new hydrogen bonds forming
between –OH and –NH2 functional groups of PLL and –CvO
Table 2 PCN characterization in DI water and cell culture media
Particle
media Composition
Particle
size (nm) PDI
Zeta
potential
(mV)
DI water DS-PLL 105 ± 0.5 0.12 ± 0.05 −25 ± 4
DS-PLL-VEGF 98 ± 7 0.28 ± 0.05 −11.20 ± 3
GT-PLL 220 ± 2 0.22 ± 0.08 −18 ± 3.5
GT-PLL-VEGF 212 ± 9 0.36 ± 0.03 −5 ± 2
Cell culture
media
DS-PLL 118.6 ± 4.1 0.411 ± 0.04 −11.43 ± 3
GT-PLL 290 ± 3.5 0.324 ± 0.06 −5.17 ± 3.8
Fig. 3 Hydrodynamic diameter (nm) and zeta potential (mV) for DS-PLL
and GT-PLL PCNs after 1, 3, and 14 days of incubation in acetate buffer
(pH = 5.5) at room temperature (25 °C).
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and –OH functional groups of GT.42 On the other hand, the
bands assigned to motions of –NH2 at 3300 cm
−1 became
invisible after complexation. This disappearance could be
related to the lower content of PLL and GT excess in the
complex NPs. Intense peaks at around 1580 cm−1 and
1720 cm−1 were also present. The peak at 1720 cm−1
probably corresponded to asymmetric stretching of –COO−
groups that might indicate polyelectrolyte complex develop-
ment. Based on FTIR analysis, it can be concluded that ionic
bonds between PLL amine groups and the carboxyl group of
GT were formed, which is in agreement with a previous
study.43
Cytocompatibility assays
To determine the in vitro cytocompatibility of the PCNs, a live/
dead assay and metabolic activity measurement were per-
formed after exposing human bone marrow stromal cells
(HS-5) to the engineered PCNs. Three doses of the PCNs (200,
400, and 800 μg mL−1) were compared to the untreated cells as
a negative control (cells in the culture medium without the
NPs). Representative live/dead stained images of the cells
treated with the PCNs as compared to the controls are shown
in Fig. 4a. The live/dead assay stains the dead cells in red and
the live cells in green. For both type of the PCNs, the viability
significantly decreased (to less than 50%), as the concentration
of the NPs increased to higher 400 μg mL−1. This drop in cell
viability at a higher concentration indicated their cytotoxicity
at high concentrations (Fig. 4b).
A PrestoBlue® assay was carried out to evaluate the cellular
metabolic activity at three dose levels of 200, 400 and 800
µg mL−1, at days 1, 3 and 5 post culture. As shown in Fig. 4c,
no statistical difference between the NPs at 200 µg mL−1 and
control was observed. Additionally, the results revealed that at
higher concentrations of the NPs (e.g. 400 and 800 µg mL−1),
the metabolic activity of the cells decreased consistently
during 5 days of culture. At NP concentrations higher than
400 μg mL−1, the NPs could prevent attachment of the cell to
the surface of the well plate.
Cell response to VEGF and preconditioned VEGF-loaded PCNs
The ability of PCNs to preserve VEGF activity was evaluated by
exposing the pre-conditioned VEGF-loaded PCNs and uncom-
plexed VEGF for 7 and 14 days to HUVECs at 37 °C in the
culture media. We used 10 ng mL−1 VEGF and 100 μg mL−1
PCNs as the final concentrations. The VEGF loading efficiency
was 93.1 ± 5% and 80.2 ± 3% for DS-PLL and GT-PLL, respect-
ively. Since there was no step to remove free VEGF, each experi-
ment (mitogenic and metabolic activity experiments) used an
equal amount of VEGF. Regarding the negative control (no
VEGF), HUVECs did not proliferate under these low-serum
Fig. 4 In vitro cytocompatibility of the polyelectrolyte NPs against HS-5 cells. (a) Representative live/dead stained images, indicating the effect of
PCN (DS-PLL and GT-PLL) dose on the cell viability at day 3 post seeding. The concentration of NPs increases from 200 to 800 μg mL−1 from left to
right. Cytotoxicity was observed for the cells treated with NPs at concentrations >400 μg mL−1. (b) Quantification of cell viability after 24 h of incu-
bation. (c) Quantification of metabolic activity of hBMSCs based on relative fluorescence units (RFU) at different incubation times (1, 3 and 5 days
post seeding). Scale bars: 100 µm. Results are presented as the mean ± STD with at least three replicates per group. The significance levels are
shown as p < 0.05 (*), p < 0.01 (**), and p < 0.0001 (****) for n = 3.
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conditions after 48 h of cell culture. Representative DAPI-
stained images in Fig. 5a show cell nuclei culturing in the low-
serum media for both VEGF bound to PCNs (DS-PLL and
GT-PLL) and VEGF in solution after 7 and 14 days. The
number of cells was normalized and compared for both VEGF
bound to PCNs and free VEGF in Fig. 5b. As the results show,
the untreated cells did not proliferate in the low-serum media.
Cell proliferation was observed for free VEGF but was signifi-
cantly lower than that of the treated cells with PCN-bound
VEGF. The normalized cell numbers for the free VEGF was stat-
istically lower than VEGF bound to PCNs (for both DS-PLL and
GT-PLL) in both pre-conditioning times. However, these values
were not statistically significant compared to the negative
control. In addition, the normalized cell numbers were more
than 1 for both of the treatments with VEGF (bound and free
VEGF), indicating that the cell numbers were enhanced as
compared to the cells cultured without the growth factor. The
mitogenic activity of VEGF bound to DS-PLL was also more
than that of VEGF bound to GT-PLL at each time point. It can
be concluded that treatment with VEGF bound to PCNs (for
both DS-PLL and GT-PLL) represents mitogenic activity over
the 14 days of pre-conditioning in the high level, while free
VEGF lost mitogenic activity by increasing the pre-condition-
ing time.
The MTT assay was used to investigate the cellular
responses to pre-conditioned VEGF during mitosis experi-
ments for 48 h. Fig. 5c demonstrates the results of the meta-
bolic activity for both types of VEGF-containing treatments.
VEGF bound to each type of PCNs demonstrated no statistical
differences over all pre-conditioning times. This result indi-
cates that based on the metabolic activity of treatments, VEGF
activity did not change during pre-conditioning. However, free
VEGF treatment showed a significant reduction in metabolic
activity after 21 days in comparison with 7 days of pre-
conditioning. At day 7 of pre-conditioning, there was no stat-
istical difference between free and treated VEGF groups.
However, by increasing the pre-conditioning time, loss of
metabolic activity of HUVECs was observed. VEGF-bound
DS-PLL showed a higher metabolic activity in comparison with
free VEGF even after 14 days of incubation, but there was no
significant difference between VEGF-bound GT-PLL and free
VEGF at this time point. Finally, after 21 days of pre-condition-
ing time, the metabolic activity of both PCNs treatments was
greater than that of VEGF alone.
Fig. 5 Cell response to VEGF and pre-conditioned VEGF-loaded PCNs through mitogenic and metabolic measurements. (a) Representative fluor-
escence images of HUVEC nuclei stained with DAPI after 2 days of culture with no treatment (negative control), VEGF-loaded PCNs (DS-PLL and
GT-PLL), and free VEGF. Pre-conditioning time does not show a significant influence on mitogenic activity, but the treatments exhibit significant
effects. (b) Quantification of VEGF mitogenic activity after 2 days of HUVEC culture for VEGF-loaded PCNs and free VEGF. The numbers represent
cell counts normalized to cell counts from the negative control. (c) The quantification of metabolic activity after 2 days of culture with VEGF-loaded
PCNs and free VEGF in solution (at different pre-conditioning times in the media up to 21 days). Metabolic activity result was normalized to the
metabolic activity of untreated HUVEC cells. Scale bars: 100 µm. Results are presented as the mean ± SEM with at least three replicates per group.
The significance levels are shown as p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001(****) for n = 3.
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Since free VEGF in solution exhibited a significantly lower
mitogenic and metabolic activity compared to VEGF bound to
both types of PCNs, the PCNs could be mainly responsible for
the high level activity of the growth factor. For the DS-PLL PCNs,
VEGF molecules could link to the PCNs over the pre-conditioning
time which, corresponds to the higher mitogenic activity of this
treatment. In addition, both PCN treatments induced more meta-
bolic activity at all pre-conditioning times compared to the nega-
tive control, indicating that VEGF remained active during the 21
days (Fig. 5c). Both GT and DS biopolymers are highly negatively
charged polysaccharides that can bind to VEGF electrostatically.
However, the glycosaminoglycan used in this work consisted of
primarily 6-Osulfated hexosamine and iduronic residue, which
are important for binding to VEGF44,45 and lack the particular
VEGF-binding sulfation, making GT less effective at stabilizing
VEGF.
Experimental
Materials
DS (from porcine intestinal mucosa, ≥90%, lyophilized
powder 60 kDa; PDI = 1.94) and PLL (0.1% (w/v) in H2O) were
purchased from Sigma-Aldrich (St Louis, MO, USA). Sodium
acetate, sodium chloride, potassium chloride, sodium phos-
phate dibasic, and potassium phosphate monobasic were pur-
chased from Merck (Germany). GT used in this study was a
high-quality ribbon type, collected from the stems of floccosus
species of Astragalus bushes, grown in the central areas of Iran.
A live/dead viability/cytotoxicity kit for mammalian cells was
purchased from Invitrogen (Eugene, OR). The PrestoBlue
reagent and Dulbecco’s phosphate buffered saline (DPBS) were
purchased from Thermo Fisher Scientific. VEGF was purchased
from R&D Systems, and MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide), 4′,6-diamidino-2-phenylindole
(DAPI), bovine serum albumin (BSA), and paraformaldehyde
were purchased from Sigma-Aldrich (St Louis, MO, USA).
Preparation of PCNs
PCNs were prepared through the drop by drop mixing of a
polycation solution with a polyanion solution and stirring vig-
orously with an excess amount of the polyanion. Two different
combinations of polycation–polyanion were used to form the
PCNs, including dermatan sulfate with poly-L-lysine (DS-PLL),
and gum tragacanth with poly-L-lysine (GT-PLL). For DS-PLL
NPs, DS (1.8 mg mL−1) and PLL (1 mg mL−1) solutions were
prepared by dissolving the biopolymers in acetate buffer (0.1
M and pH = 5.5) under magnetic stirring. The solutions were
then filtered by using syringe filters (0.22 μm, Fisher Scientific,
PA) to remove particles, precipitates, and undissolved powders.
The PLL solution was then added drop by drop to DS in excess
at different polycation : polyanion volume ratios (1 : 5, 1 : 6,
1 : 7 and 1 : 10) under vigorous stirring.
A similar procedure was used for GT-PLL with some modifi-
cations. PLL (1 mg mL−1) was mixed with GT (1.8 mg mL−1) at
different polycation : polyanion volume ratios (1 : 5, 1 : 6, 1 : 7 and
1 : 10). The mixtures were left for 24 h to settle and to separate the
aggregated part. The supernatant solutions were decanted and
centrifuged at 12 000 rpm for 15 min, and finally, the precipitates
were freeze-dried (vacuum: 9 Pa, −50 °C; LaBCONCO, USA). The
production yield was determined based on the mass of the dried
PCNs relative to the dry mass of the starting polymers.
Material characterization
Size and morphology of the PCN NPs were examined by scan-
ning electron microscopy (SEM, TEscan, MIRA3, Czech
Republic) and transmission electron microscopy (TEM, Zeiss –
EM10C). The dried NPs were dispersed in DI water to attain
dilute suspensions. For SEM imaging, the suspensions were
placed onto aluminum foil and left to dry at room temperature
and gold-coated using an Edwards Sputter Coater (DST1-2,
Nanostructured Coatings Co., Iran). SEM images were taken at
2 kV. The mean diameter of the NPs was calculated by measur-
ing the diameter of at least 50 random NPs for each sample
from their SEM images using Image J software (National
Institute of Health, Bethesda, MD).
For TEM imaging, a drop of the diluted suspension was
placed on a copper-coated grid (Formvar/carbon 200 mesh,
copper), and TEM analysis was performed at 80 kV. The hydro-
dynamic size distribution of the NPs was determined using
dynamic light scattering (Zetasizer Ver. 6.00, MALVERN, UK)
in DI water and cell culture media (α-MEM). The surface
charge of the PCNs in DI water at 25 °C was measured using a
ZetaPALS instrument (Zetasizer Ver. 6.00, MALVERN, UK) in
both DI water and cell culture media (α-MEM). Fourier trans-
form infrared (FTIR) spectra of the NPs were recorded using a
PerkinElmer instrument (RX, USA) between 450 and
4000 cm−1 with a resolution of 1 cm−1.
Cytocompatibility
HS-5 cells from human bone marrow/stroma (obtained from
ATCC, Manassas, USA) were cultured at 37 °C in a 5% CO2 and
humidified atmosphere in Minimum Essential Medium α
(α-MEM, Gibco, Thermo Fisher Scientific). The medium was
supplemented with FBS (10%v/v) and penicillin/streptomycin
(1%v/v). At 70% confluency, the cells were used for the evalu-
ation of cell viability and metabolic activity. The biocompatibil-
ity of different concentrations of PCNs (200, 400 and
800 μg mL−1) towards HS-5 cells was evaluated through cell
viability and metabolic activity assessments.
To evaluate the cell viability after contact with PCNs, a com-
mercial live/dead assay kit was used.46,47 To do this, the cells
were first seeded in a 24-well plate at a density of 20 000 cells
per cm2, and then 1 mL of α-MEM containing 10% FBS was
added to each well. The cells were allowed to attach for 4 h.
PCNs, DS-PLL, and GT-PLL were then diluted with α-MEM to 3
different concentrations (200, 400, and 800 μg mL−1). After cel-
lular attachment, the resulting solutions were added to the
cells. The untreated cell-seeded wells were used as the control.
The cells were then incubated at 37 °C in 5% CO2 for 24 h. The
media were aspirated, followed by washing three times with
DPBS before live/dead staining.
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To perform the live/dead assay, the cells were stained with
ethidium homodimer-1 (EthD-1, 2 μl ml−1 in DPBS) for the
dead cells and Calcein AM (0.5 μl ml−1 in DPBS) for the live
cells. 400 μL of dye solution was added to each well, and the
plates were incubated in the culture incubator for 15 min at
37 °C. For each well, three images were taken by an inverted
fluorescence microscope (Zeiss Axio Observer Z1). Live and
dead cells were counted using the ImageJ software, and the
viability was reported by calculating the number of live cells
divided by the total cell number containing live and dead
cells.
The measurement of metabolic activity of the cells was per-
formed on days 1, 3, and 5 using a PrestoBlue® assay accord-
ing to the manufacturer’s protocol. Briefly, the cells treated
with PCNs were incubated with a solution containing 10%
PrestoBlue® reagent and 90% cell culture medium for 45 min
at 37 °C. The final fluorescence was recorded at 535–560 nm
excitation and 590–615 nm emission. Relative fluorescence
values were calculated and reported for each time point.
Formation of VEGF loaded PCNs
VEGF in DPBS was added to PCN solutions (1 mg mL−1) to
make 100 ng mL−1 final concentration of the growth factor
under stirring for 30 min. The growth factor loaded PCNs were
then centrifuged (9000 rcf for 10 min). The supernatants were
diluted to obtain VEGF concentration in the range of the
ELISA. To evaluate the VEGF loading efficiency with the PCNs,
an ELISA VEGF kit (R&D System, PeproTech, USA) was used.
The growth factor bound to PCNs was measured by subtracting
the VEGF concentration in the supernatants from the initial
loaded VEGF in the solution.
Culture of HUVECs
HUVECs (CC-2519, Lonza Group, Basel, Switzerland) were cul-
tured at 37 °C, 5% CO2, and humidified atmosphere in EGM-2.
The basal medium (not supplemented with VEGF, EGF, bFGF,
and IGF) was used to evaluate cell metabolic and mitogenic
behavior.
Pre-conditioning VEGF and VEGF-loaded PCNs
To investigate the capability of the PCNs to immobilize VEGF,
VEGF-loaded PCNs and unbound (free) VEGF were first pre-con-
ditioned through incubation in the cell culture media contain-
ing 10% FBS at different time points (7, 14, or 21 days and
37 °C) to destabilize VEGF. Finally, the activity of VEGF was eval-
uated through investigating the mitosis and metabolic ability of
HUVECs in the low serum media to prevent the interaction
between the different compositions in the cell culture media
with the growth factors that should be tested. The same pro-
cedure (described in VEGF loaded PCNs) was used to load VEGF
to each PCN type (DS-PLL and GT-PLL) without centrifugation.
Cell response to unbound VEGF and VEGF-loaded PCNs
To evaluate the ability of PCNs to stabilize the growth factor,
HUVECs were cultured in the presence of free and bound
VEGF in the low-serum cell culture media. HUVECs’ mitogenic
properties were assayed after 48 h of culture using the DAPI
staining, imaging and counting the nuclei. Finally, the meta-
bolic activity of treated cells was assessed by the MTT assay
after 48 h of culture.
Mitogenic activity assay. The HUVEC proliferation assay was
performed to indicate the activity of pre-conditioned VEGF
after 7 and 14 days in the cell culture media at 37 °C. The cell
density was 3000 cells per cm2. Pre-conditioned VEGF-loaded
PCNs and free VEGF were both tested. Firstly, the cells were
incubated for 2 h to attach to the surface of the plate by
adding 0.5 mL of the untreated media containing 10% FBS in
a 48-well plate. The seeding media were then aspirated and
replaced with 0.5 mL of the low-serum media containing the
pre-conditioned VEGF-loaded PCNs and free VEGF. PCN treat-
ments were diluted using the low serum media to 100 μg mL−1
(PCN) containing 10 ng mL−1 VEGF final concentration. Free
VEGF treatment was also diluted to 10 ng mL−1. The cell
nuclei were stained using 4′,6-diamidino-2-phenylindole
(DAPI). Briefly, the cells were fixed in 4% (v/v) paraformalde-
hyde (Sigma) for 20 min and then permeabilized with 0.1%
(w/v) Triton X-100 solution in DPBS for 45 min. Next, 1% (w/v)
bovine serum albumin (BSA) solution in DPBS was used to
block the samples for 20 min. The samples were stained with
1 µL mL−1 DAPI in DPBS for 5 min and washed three times
with DPBS. The stained samples were kept at 4 °C in the dark
until taking the images. Three nonoverlapping images were
taken from each sample. The ImageJ software (National
Institutes of Health, USA) was used to process the images. The
cell number per area was calculated by the counting of the cell
nuclei using the particle analyzer algorithm in the ImageJ soft-
ware. Finally, the VEGF activity was recorded as the mean cell
number per area of each sample and normalized through the
average cells per area in the untreated samples as a control
(without VEGF).
Metabolic activity measurement. To investigate the effect of
VEGF on the cells, the metabolic activity of the cells were eval-
uated by MTT assays at days 7, 14, and 21 after precondition-
ing periods. All treatments were conducted in triplicate with
the cell seeding density of 104 cells per cm2. The cells were
incubated for 2 h to attach to the surface of the well plates
with 0.5 mL of the non-treated media supplemented with 10%
FBS. The media were taken and replaced with 0.5 mL of the
low-serum media containing the treatment (preconditioned
VEGF bound to each type of PCNs and free VEGF). All treat-
ments were added to the media to obtain the same final con-
centrations in the mitosis assay as explained before. The MTT
assay was performed according to the manufacturer’s instruc-
tions after 48 h of culture. Finally, the VEGF activity was
reported as the average of all readings for each sample and
then normalized based on the negative control (no VEGF).
Conclusions
The biomimetic proteoglycan PCNs were developed using a
polymer–polymer pair interaction based on cationic (PLL) and
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anionic (DS and GT) polymers with no use of crosslinker,
surfactant and organic solvents or further chemical
functionalization to bind the growth factor. The negatively
charged PCNs can easily bind to the positively charged drug
and growth factors, which makes them suitable candidates for
the delivery of therapeutics. It was shown that at concen-
trations of 200 μg mL−1 and above, the NPs could prevent
attachment of the cells to well plates, and at higher concen-
trations, they may show cytotoxic effects toward HS-5 cells. The
result also determined the time- and dose-dependent HS-5
cells’ metabolic activity.
The results confirmed that the mitogenic activity of VEGF
was maintained after binding well to DS-PLL PCNs. Free VEGF
in solution did not show significant mitogenic properties
during all incubation periods. Additionally, during the equal
pre-conditioning time periods, delivery of VEGF using both
types of PCNs showed a higher metabolic activity compared to
free VEGF. This could enhance the prospects for the delivery of
therapeutics using nanoparticle immobilized growth factors or
cytokines for tissue regeneration applications.
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